Citi keeps a Neutral rating and $260 price target on Becton Dickinson while noting that the firm is opening a 90-day Positive Catalyst Watch on the stock. The significant headwinds, including FX and “outsized” inflation, that impacted Q1 margins should begin to abate, while the management starts to deliver with scaling ramp of Alaris into the end of FY24, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Citi opens ‘positive catalyst watch’ on Becton Dickinson into earnings
- AngioDynamics settles litigation with Becton Dickinson
- Upcoming Deadline to Share in Becton, Dickinson and Company (BDX) Class Action Settlement
- 5 Best Healthcare Stocks to Buy in March 2024, According to Analysts
- Becton Dickinson further increases U.S. syringe production
